Why Pharma & Biomed Companies’ Risk Analysis Processes are Due for a Check-Up
Posted on 07-18-2018 by Lisa Thompson

Just three years ago, Teva Pharmaceuticals, a drug-maker in Israel, disclosed to both the U.S. Securities & Exchange Commission and the U.S. Department of Justice that an on-going internal probe had revealed possible violations of the Foreign Corrupt Practices Act (FCPA) and/or local laws. Ultimately... Read More

Novartis bribery allegations highlight compliance risks in pharma
Posted on 05-23-2017 by Ulyana Androsova

Recent allegations that Novartis bribed doctors in Greece serve as a reminder that the pharmaceutical industry has a high risk of bribery and corruption. We look at the reasons behind the risk, and how companies can enhance compliance risk mitigation. New markets for pharma increase bribery and corruption... Read More